Accenture 4Q Earnings Climb on Higher Bookings, AI Demand
By Dean Seal
Accenture closed out its fiscal year with higher quarterly earnings and revenue as new bookings shot up, with $1 billion of them coming from its generative artificial-technology services.
The Dublin professional-services company posted net income of $1.68 billion, or $2.66 a share, for the fiscal fourth quarter ended Aug. 31, compared with $1.37 billion, or $2.15 a share, in the same quarter last year.
Stripping out one-time items, adjusted earnings were $2.79 a share. Analysts polled by FactSet expected$2.78 a share.
Revenue rose 5% to $16.41 billion, ahead of analyst estimates for $16.37 billion, according to FactSet. Consulting revenue edged up 1% to $8.26 billion, while managed services revenue rose 5%.
New bookings were up 21% at $20.1 billion, with new bookings tied to generative AI hitting $1 billion during the quarter.
Accenture is guiding for revenue to rise 3% to 6% in the fiscal year ahead, which started Sept. 1. Earnings for fiscal 2025 are set to come in 10% to 13% higher at $12.55 to $12.91 a share, in line with current analyst projections for $12.82.
Shares rose 5.6% to $356 in pre-open trading.
Write to Dean Seal at dean.seal@wsj.com
(END) Dow Jones Newswires
September 26, 2024 07:28 ET (11:28 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
What’s the Difference Between the CPI and PCE Indexes?
-
Micron Earnings: Great Guidance but Stock Now Looks Fairly Valued
-
August PCE Report Forecasts Show More Good News on Inflation
-
AI Stocks May Be Down, but Don’t Count Them Out
-
4 Stocks to Buy as the Fed Cuts Interest Rates
-
Markets Brief: The Uncertain Path to Neutral Interest Rates
-
What’s Happening in the Markets This Week
-
Where Top Stock Fund Managers Are Looking Next After the Fed Rate Cut
-
Our Top Pick for Investing in US Renewable Energy
-
Undervalued by 25% and Yielding 5%, This Stock Is a Buy
-
Can AI Predict Future Stock Returns?
-
The Best Energy Stocks to Buy Now
-
10 Undervalued Wide-Moat Stocks
-
Obesity Drugs: Can New Firms Take Market Share From Eli Lilly and Novo Nordisk?
-
New 4-Star Stocks
-
Intel Fair Value Left Unchanged Despite Qualcomm Takeover Talk